

NOTICE IS GIVEN that the Annual General Meeting of CogState Limited (ABN 80 090 075 723) (the "**Company**") will be held on Thursday 23<sup>rd</sup> October 2014 at the offices of Pitcher Partners (Company Auditor) at Level 19, 15 William Street, Melbourne, at 9:30am (Melbourne time).

## ORDINARY BUSINESS

### 1. Financial Statement and Reports

To receive and consider the Financial Statements and the Reports of the Directors and of the Auditor for the year ended 30 June 2014.

### 2. Remuneration Report (non-binding vote)

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

*That the Remuneration Report as disclosed in the Annual Directors Report for the year ended 30 June 2014 be adopted.*

*Note – the vote on this resolution is advisory only and does not bind the Directors or the Company.*

The voting exclusion statement for this resolution is set out in Item 2 of the Explanatory Notes to the Notice of Meeting.

### 3. Election of Directors

#### a. Election of Director – Mr David Dolby

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

*That Mr David Dolby, who was appointed by the Board as a Director on 23 November 2013 and retires in accordance with clause 48.1 of the Company's Constitution, being eligible for election, be elected as a Director of the Company.*

#### b. Re-Election of Director – Mr Martyn Myer

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

*That Mr Martyn Myer, a Director of the Company who retires by rotation at this Annual General Meeting in accordance with clause 48.1 of the Company's Constitution and, being eligible, offers himself for re-election, be elected as a Director of the Company.*

### 4. Special Resolution – Approval of additional 10% Placement Facility

To consider and, if thought fit, pass the following resolution as a special resolution:

*That, for the purpose of ASX Listing Rule 7.1A and for all other purposes, shareholders approve the issue of equity securities of up to 10% of the total issued capital of the Company (at the time of the issue), calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 over a 12 month period and on the terms and conditions set out in the Explanatory Notes to the Notice of Meeting.*

The voting exclusion statement for this resolution is set out in Item 4 of the Explanatory Notes to the Notice of Meeting.



## **5. Cogstate Employee Share Option Plan**

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

*That, for the purposes of ASX Listing Rule 7.2 (Exception 9) and for all other purposes, the Company approves the terms of the Cogstate Employee Share Option Plan as described in the Explanatory Notes to the Notice of Meeting, and the grant of options under those Plan.*

The voting exclusion statement for this resolution is set out in Item 5 of the Explanatory Notes to the Notice of Meeting.

## **6. Cogstate Non-Executive Director Share Option Plan**

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

*That, for the purposes of ASX Listing Rule 7.2 (Exception 9) and for all other purposes, the Company approves the terms of the Cogstate Non-Executive Director Share Option Plan as described in the Explanatory Notes to the Notice of Meeting, and the grant of options under those Plan.*

The voting exclusion statement for this resolution is set out in Item 6 of the Explanatory Notes to the Notice of Meeting.



## PROXIES

A proxy form is enclosed. A shareholder entitled to attend and vote at the meeting has a right to appoint a proxy and that person need not be a shareholder of the Company. A proxy can be an individual or a body corporate. A shareholder who is entitled to cast 2 or more votes may appoint 2 proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If a shareholder appoints two proxies and the proportion or the number of the shareholders' votes each proxy may exercise is not specified, each proxy may exercise half the votes. If more than one proxy for a member is present at the meeting, only the first named proxy may vote on a show of hands.

If an attorney is to attend the meeting, or if a proxy form is executed by an attorney, the relevant certified power of attorney is to be submitted to the Company's Share Registry for noting and return, at least 48 hours before the commencement of the meeting or any adjournment of the meeting.

A shareholder which is a body corporate and which is entitled to attend and vote at the meeting, or a proxy which is a body corporate and which is appointed by a member of the Company entitled to attend and vote at the meeting, may appoint a person to act as its representative at the meeting by providing that person with an appropriately executed Letter of Representation (obtainable from the Company's Share Registry). A copy of the signed Letter of Representation, or other evidence satisfactory to the Chairman of the meeting, must be produced prior to admission to the meeting.

Hard copies of the Annual Report have only been sent to those shareholders who have elected to receive one. The Annual Report can be viewed or downloaded online on the Company's website at [www.cogstate.com](http://www.cogstate.com).

To be valid, proxies must be received by one of the following methods not less than 48 hours before the commencement of the meeting or any adjournment of the meeting:

### By delivery to the Company's Share Registry

Online: [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au)

Hand delivery: Link Market Services Limited  
Level 12, 680 George Street  
Sydney, NSW, 2000

Postal Address: Locked Bag A14  
Sydney South, NSW, 1235

Facsimile: (02) 9287 0309

## VOTING ENTITLEMENT

The Directors have determined in accordance with the Corporations Regulations 2001 (Cth) that, for the purposes of determining voting entitlements at the Annual General Meeting, shares will be taken to be held by the registered holders at 7.00 pm Melbourne time on Tuesday 21st October 2014.

BY ORDER OF THE BOARD



Claire Newstead-Sinclair  
Company Secretary

19 September 2014



**COGSTATE**  
ASSESS • MONITOR • IMPROVE

2014 Notice of Annual General Meeting



## Explanatory Notes

### Item 1 – Receive and consider the financial and other reports

The Corporations Act 2001 (Cth) ("**Corporations Act**") requires the Financial Report, Directors' Report and Auditor's Report to be laid before the meeting. There is no requirement in the Corporations Act or the Company's Constitution for shareholders to vote on, approve or adopt these reports.

Shareholders will have a reasonable opportunity to ask questions and make comments on these reports and on the management of the Company.

### Item 2 – Remuneration Report (non-binding vote)

The Board submits its Remuneration Report to shareholders for consideration and adoption by way of non-binding resolution. The Directors will consider the outcome of the vote and comments made by the shareholders on the Remuneration Report at the meeting when reviewing the Company's remuneration policies.

This resolution is advisory only and does not bind the Directors or the Company. However, if 25% of the votes that are cast are voted against the adoption of the Remuneration Report at two consecutive AGMs, shareholders will be required to vote at the second of those AGMs on a resolution (a "spill resolution") that another meeting be held within 90 days at which those of the Company's Directors (other than the Managing Director) who held office when the resolution was passed to make the Directors' Report considered at the second AGM must stand for re-election.

The Remuneration Report is set out in the Directors' Report in the 2014 Annual Report. The Remuneration Report:

- Explains the Board's policy for determining the nature and amount of remuneration of executive Directors and senior executives of the Company;
- Discusses the relationship between the Board's remuneration policy and the Company's performance;
- Sets out the actual remuneration for the financial year ended 30 June 2014 for each Director and each member of the Company's senior executive management team; and
- Details and explains any performance hurdles applicable to the remuneration of executive Directors and senior executives of the Company.

A reasonable opportunity will be provided for discussion of and questions relating to the Remuneration Report at the meeting.

The Board considers that the Company's remuneration policies are structured to provide rewards based on its performance and are competitive with those in the markets in which it operates. On that basis, and with each Director acknowledging their own personal interest, the board unanimously recommends that shareholders vote in favour of the Remuneration Report.

**Voting exclusion statement** - No votes can be cast by or on behalf of a member of Key Management Personnel (as identified in the Remuneration Report) ("**KMP**") and their closely related parties (collectively referred to as a "**Prohibited Voter**"). However, a Prohibited Voter may vote directed proxies for someone other than a Prohibited Voter and the Chairman may vote as proxy for someone other than a Prohibited Voter in accordance with a direction on the proxy form to vote as the proxy decides.

The Chairman of the meeting intends to vote undirected proxies in favour of Item 2.



If the Chairman of the Meeting is appointed as your proxy, or if the Chairman of the Meeting becomes your proxy by default, and you do not provide a voting direction, you are expressly authorising the Chairman of the Meeting to exercise your proxy even if the resolution is connected directly or indirectly with the remuneration of a member of the KMP.

### Item 3 – Election of Directors

The following information has been provided by the candidates in support of their election as director.

**a. Mr David Dolby BSE MBA (Non-Executive Director)**

In accordance with clause 48.1 of the Company's Constitution, Mr Dolby retires from the Board and being eligible, and having nominated in accordance with the Company's Constitution, offers himself for election as a Director of the Company.

Mr Dolby is a non-executive Director appointed on 23 November 2013. He sits on the Audit and Compliance Committee as well as the Remuneration and Nomination Committee.

David holds a BSE in Civil Engineering from Duke University, and an MBA from the Stanford Graduate School of Business. David is managing director at Dolby Family Ventures LP, and represents the Dolby Family Trust on a number of technology, scientific research, and consumer products investments focusing on innovation and commercialising intellectual property. David has been a member of the Board of Directors and a member of the Technology Strategy Committee of Dolby Laboratories since 2011, and previously served as Manager, Strategic Partnerships. In this role, David was responsible for managing strategic partnerships and technology standards. David serves as chair of the Audit Committee for the Ray and Dagma Dolby Family Fund, focusing on philanthropic grants as well as mission driven impact investments in medical research and advocacy. David's experience also includes roles at Kaleidescape, Inc, a company focussed on high-performance music and movie server systems, and NetVMG, which developed route control software. Previously, David was an investment banking analyst focussed on technology with Perseus Group (now GCA Savvian).

The Directors (other than Mr Dolby) unanimously recommend that shareholders vote for the election of Mr Dolby.

**b. Mr Martyn Myer AO, BE, MEng, MSM. (Chair and Non-Executive Director)**

In accordance with clause 48.1 of the Company's Constitution, Martyn Myer AO retires from the Board and seeks re-election as a Director at the Meeting.

Mr Myer is Chairman of CogState Limited. Mr Myer also chairs the Remuneration and Nomination Committee and the Audit and Compliance Committee. Until 30 June 2007 he was President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of the Florey Neuroscience Institutes until May 2010. At the Howard Florey Institute he participated in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases. Mr Myer was appointed to the Council of the University of Melbourne in February 2010. Mr Myer obtained his Master of Science in Management at MIT in Boston, and his Master of Engineering Science at Monash University, Melbourne.

During the last three years, Mr Myer has also served as a director of the following listed companies:

- Diversified United Investment Ltd - Appointed: 23 September 1991 Retired 16 November 2011

Mr Myer is also a director of CogState Inc., CogState Sport Inc., Axon Sports Pty Ltd, CogState Canada Inc and Cogstate Spain SL.

The Directors (other than Mr Myer) unanimously recommend that shareholders vote for the re-election of Mr Myer.





## Item 4 – Approval of additional 10% Placement Facility

### Purpose

The purpose of this resolution is to authorise the Company to issue a further 10% of its issued share capital under ASX Listing Rule 7.1A during the 10% Placement Period (as defined below) in addition to and without using the Company's 15% placement capacity under ASX Listing Rule 7.1. This would effectively provide the Company with a total placement capacity of 25% (less that part of its placement capacity not available under ASX Listing Rule 7.1).

### General

ASX Listing Rule 7.1A enables "eligible entities" to seek shareholder approval (by special resolution) at an annual general meeting, to issue equity securities of up to 10% of its total issued capital during the 12 month period after the annual general meeting ("**10% Placement Facility**").

An "eligible entity" for the purposes of ASX Listing Rule 7.1A is an entity that (as at the date of the annual general meeting):

- is not included in the S&P / ASX 300 Index; and
- has a market capitalisation of \$300 million or less.

As at the date of these Explanatory Notes, the Company is an "eligible entity" for the purposes of ASX Listing Rule 7.1A.

Any equity securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of equity securities of the Company. The Company, as at the date of this Notice of Meeting has on issue one class of equity securities, namely ordinary shares (ASX Code: CGS).

The Company is seeking shareholder approval by a special resolution to have the ability to issue equity securities under the 10% Placement Facility. The exact number of equity securities to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and described below.

### Formula for calculating 10% Placement Facility

ASX Listing Rule 7.1A.2 provides that eligible entities that have obtained shareholder approval under ASX Listing Rule 7.1A may issue, or agree to issue, a number of equity securities calculated in accordance with the following formula:

$$(A \times D) - E$$

A = The number of fully paid shares on issue 12 months before the date of issue or agreement to issue:

- plus the number of fully paid shares issued in the 12 months under an exception in ASX Listing Rule 7.2;
- plus the number of partly paid shares that became fully paid in the 12 months;
- plus the number of fully paid shares issued in the 12 months with approval of shareholders under ASX Listing Rules 7.1 or 7.4; and
- less the number of fully paid shares cancelled in the 12 months.

D = 10%.

E = The number of equity securities issued or agreed to be issued under ASX Listing Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue, that are not issued with the approval of shareholders under ASX Listing Rules 7.1 or 7.4.



## Specific disclosures required by ASX Listing Rule 7.3A

Pursuant to and in accordance with ASX Listing Rule 7.3A, the below information is provided in relation to the approval of the 10% Placement Facility:

### a. Issue Price

The equity securities (if any) will be issued at an issue price of not less than 75% of the volume weighted average price of the Company's equity securities in that class over the 15 trading days on which trades in that class were recorded immediately before:

- i. the date on which the price at which the securities are to be issued is agreed; or
- ii. if the securities are not issued within 5 trading days of the date mentioned in paragraph (i) above, the date on which the securities are issued.

### b. Risk of Economic and Voting Dilution

If this resolution is approved by shareholders and the Company issues shares under the 10% Placement Facility, the existing shareholders' voting power in the Company will be diluted as shown in Table 1.

There is a risk that:

- the market price for the Company's equity securities in that class may be significantly lower on the date of the issue of the equity securities than on the date of the approval under Listing Rule 7.1A; and
- the equity securities may be issued at a price that is at a discount to the market price for the Company's equity securities on the issue date.

Table 1

Table 1 shows the dilution of existing shareholders on the basis of the current market price of shares and the current number of ordinary securities for variable "A" calculated in accordance with the formula in ASX Listing Rule 7.1A.2 as at the date of this Notice of Meeting. The table also shows the voting dilution impact where the number of shares on issue (variable A in the formula) changes and the economic dilution where there are changes in the issue price of shares issued under the 10% Placement Capacity.

Number of Shares on issue	Number of Shares that may be issued under 10% Placement Facility	Dilution		
		Funds raised based on issue price of \$0.1375 (50% decrease in current issue price)	Funds raised based on issue price of \$0.275 (current issue price)	Funds raised based on issue price of \$0.4125 (50% increase in current issue price)
99,004,811	9,900,481	\$1,361,316	\$2,722,632	\$4,083,948
148,507,217 (50% increase)	14,850,722	\$2,041,974	\$4,083,948	\$6,125,923
198,009,622 (100% increase)*	19,800,962	\$2,722,632	\$5,445,265	\$8,167,897





\* The number of shares on issue (variable "A" in the formula) could increase as a result of the issue of shares that do not require shareholder approval under ASX Listing Rule 7.1 or that are issued with shareholder approval under ASX Listing Rule 7.1.

Table 1 has been prepared on the following assumptions:

- the current shares on issue are the shares on issue as at the date of this Explanatory Note;
- the current issue price set out above is the closing price of the shares on the ASX on 11 September 2014;
- the Company issues the maximum number of shares available under the 10% Placement Facility; and
- No options are exercised into shares before the date of the issue of the shares under the 10% Placement Facility.

#### **c. Issue date**

The Company will only issue equity securities under the 10% Placement Facility during the 10% Placement Period (as defined below).

Shareholder approval under ASX Listing Rule 7.1A is valid from the date of shareholder approval until the earlier of:

- the date that is 12 months after the date of approval under ASX Listing Rule 7.1A; or
- the date the Company obtains shareholder approval for a transaction under ASX Listing Rule 11.1.2 (significant change to nature or scale of activities) or ASX Listing Rule 11.2 (disposal of main undertaking),

("10% Placement Period").

#### **d. Purpose of Issue**

The Company may seek to issue the equity securities under the 10% Placement Facility for:

- cash consideration. The Company may use the funds raised (without limitation):
  - o in the pursuit of commercialising Cogstate technology in the Healthcare area (that is, use of Cogstate technology by primary care physicians), including but not limited to the pursuit of required regulatory registrations and staff additions to facilitate an expansion into strategic territories around the world;
  - o to help continue Cogstate's Research & Developments and Precision Recruitment efforts, with a particular focus on Alzheimer's disease specifically, as well as other types of dementia;
  - o general working capital; and
- non-cash consideration. This may include (without limitation) an acquisition of new assets and other investments. If such circumstances arise, the Company will provide a valuation of the non-cash consideration as required by ASX Listing Rule 7.1A.3.

There are no current proposals to utilise the 10% Placement Facility. Should any specific proposals be approved by the Board, the Company will announce same to ASX as required by its continuous disclosure obligations.





#### **e. Allocation Policy**

The Company will comply with the disclosure obligations under ASX Listing Rules 7.1A.4 and 3.10.5A upon issue of any equity securities using the 10% Placement Facility. The Company's allocation policy will be dependent on the prevailing market conditions at the time of any proposed issue. The identity of the allottees of equity securities will be determined on a case-by-case basis having regard to a range of factors, including but not limited to, the following:

- the methods for raising funds that are available to the Company, including but not limited to, a rights issue and other fundraising structures in which existing security holders can participate;
- the effect of the issue of the shares on the control of the Company;
- the financial situation and solvency of the Company; and
- advice from corporate, financial and broking advisers (if applicable).

The allottees under the 10% Placement Facility have not been determined as at the date of this Notice of Meeting but may include existing substantial shareholders and/or new shareholders who are not related parties or associates of a related party of the Company.

#### **f. Previous Approval under ASX Listing Rule 7.1A**

The Company previously obtained shareholder approval under ASX Listing Rule 7.1A at the annual general meeting on 23 October 2013. However, the Company has not issued any equity securities under ASX Listing Rule 7.1A since that date.

In accordance with ASX Listing Rule 7.3A.6, the following information is provided to shareholders regarding the equity securities issued in the previous 12 months preceding the date of the Annual General Meeting (that is, since 23 October 2013):

##### **Listing Rule 7.3A.6(a)**

The table below shows the total number of equity securities issued in the previous 12 months preceding the date of the Annual General Meeting and the percentage that those issues represent of the total number of equity securities on issue at the commencement of that 12 month period.

Total number of equity securities issued in the 12 months preceding the date of the meeting	22,319,848
Percentage that they represent of the total number of equity securities on issue at the commencement of that 12 month period	28.59%



**Listing Rule 7.3A.6(b)**

The tables below set out specific details for each issue of equity securities that have taken place in the 12 month period preceding the date of the Annual General Meeting.

<b>Date of issue</b>	<b>31 October 2013</b>
Number issued	450,000 Non-Executive Director and Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	Non-Executive Directors and CEO
Price	\$0.49
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

<b>Date of issue</b>	<b>12 November 2013</b>
Number issued	150,000 fully paid ordinary shares
Summary of terms	Investor Options exercised. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Campbell Taylor
Price	\$0.3750
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$56,250
Amount of cash consideration spent	\$56,250
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A





<b>Date of issue</b>	<b>20 November 2013</b>
Number issued	268,959 fully paid ordinary shares
Summary of terms	Investor Options exercised. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Martyn Myer
Price	\$0.3750
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$100,860
Amount of cash consideration spent	\$100,860
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

<b>Date of issue</b>	<b>20 November 2013</b>
Number issued	9,364,865 fully paid ordinary shares
Summary of terms	Private placement. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Dagmar Dolby and Douglas Rosenberg
Price	\$0.37
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$3,465,000
Amount of cash consideration spent	\$3,465,000
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A



<b>Date of issue</b>	<b>22 November 2013</b>
Number issued	50,000 fully paid ordinary shares
Summary of terms	Non-Executive Director options exercised. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	David Simpson
Price	\$0.24
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$12,000
Amount of cash consideration spent	\$12,000
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

<b>Date of issue</b>	<b>22 November 2013</b>
Number issued	73,492 fully paid ordinary shares
Summary of terms	Investor options exercised. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Brad O'Connor
Price	\$0.2727
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$20,041
Amount of cash consideration spent	\$20,041
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A





<b>Date of issue</b>	<b>20 December 2013</b>
Number issued	101,051 fully paid ordinary shares
Summary of terms	Investor options exercised. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Rachael Kohler
Price	\$0.3750 and \$0.2727
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$30,376
Amount of cash consideration spent	\$30,376
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

<b>Date of issue</b>	<b>23 December 2013</b>
Number issued	10,777,057 fully paid ordinary shares
Summary of terms	Rights issue to all shareholders of 1 share for every 8 ordinary shares at an issue price of \$0.37. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Offer made to all shareholders
Price	\$0.37
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$3,987,511
Amount of cash consideration spent	\$3,987,511
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A



<b>Date of issue</b>	<b>21 January 2014</b>
Number issued	99,424 fully paid ordinary shares
Summary of terms	Investor options exercised. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Campbell Taylor
Price	\$0.2727
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$27,113
Amount of cash consideration spent	\$27,113
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

  

<b>Date of issue</b>	<b>2 April 2014</b>
Number issued	25,000 Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	New employee
Price	\$0.36
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A





<b>Date of issue</b>	<b>2 June 2014</b>
Number issued	750,000 Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	New employee
Price	\$0.28
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

<b>Date of issue</b>	<b>7 July 2014</b>
Number issued	20,000 Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	New employee
Price	\$0.30
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A



<b>Date of issue</b>	<b>23 July 2014</b>
Number issued	50,000 Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	New employee
Price	\$0.29
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

<b>Date of issue</b>	<b>1 August 2014</b>
Number issued	20,000 Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	New employee
Price	\$0.28
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A





<b>Date of issue</b>	<b>4 August 2014</b>
Number issued	20,000 Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	New employee
Price	\$0.28
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

<b>Date of issue</b>	<b>27 August 2014</b>
Number issued	50,000 fully paid ordinary shares
Summary of terms	Employee options exercised. Shares issued rank pari passu with all other fully paid ordinary shares on issue.
Names of the persons who received securities or basis on which those persons were determined	Peter Snyder
Price	\$0.24
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	\$12,000
Amount of cash consideration spent	\$12,000
Use of cash consideration	Working capital
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A



<b>Date of issue</b>	<b>2 September 2014</b>
Number issued	50,000 Employee Options granted
Summary of terms	One third of options vest after two years, the remaining two thirds of options vest after three years and the options expire after five years.
Names of the persons who received securities or basis on which those persons were determined	New employee
Price	\$0.32
Discount to market price (if any)	N/A
<b>For cash issues</b>	
Total cash consideration received	N/A
Amount of cash consideration spent	N/A
Use of cash consideration	N/A
Intended use for remaining amount of cash (if any)	N/A
<b>For non-cash issues</b>	
Non-cash consideration paid	N/A
Current value of that non-cash consideration	N/A

### **Voting Exclusion Statement**

In accordance with ASX Listing Rules 7.3A.7 and 14.11, the Company will disregard any votes cast on this resolution by:

- a person who may participate in the proposed issue of equity securities under the 10% Placement Facility, and any person who might obtain a benefit (except a benefit solely in the capacity of a shareholder), if this resolution is passed; and
- any associate of a person referred to above.

However, the Company need not disregard a vote if:

- it is cast by the person as proxy for a person who is entitled to vote, in accordance with directions on the proxy form; or
- it is cast by the Chairman as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

At the date of this Notice of Meeting, the Company has not approached any particular existing shareholder or security holder or an identifiable class of existing security holder to participate in the issue of equity securities under the 10% Placement Facility. Therefore, no existing shareholder's votes will be excluded under the above voting exclusion.

### **Board Recommendation**

The Board unanimously recommends that shareholders vote in favour of this resolution.

The Chairman intends to vote undirected proxies in favour of this resolution.





## Item 5 - Cogstate Employee Share Option Plan

### Background

The Board has established the Cogstate Employee Share Options Plans (the "**Plans**") to reward executives and employees in a manner which aligns their long term incentives with the creation of shareholder wealth. The Plan was last approved by shareholders at the Company's 2010 annual general meeting.

### Purpose of Item 5

Item 5 seeks shareholder approval for the Plan pursuant to ASX Listing Rule 7.2 (Exception 9).

ASX Listing Rule 7.1 requires shareholder approval for an issue of equity securities if, over a 12 month period, the number of equity securities issued is more than 15% of the number of ordinary shares on issue at the start of that 12 month period.

ASX Listing Rule 7.2 (Exception 9) provides that an issue of equity securities under an employee incentive scheme does not detract from the available 15% limit under ASX Listing Rule 7.1 if shareholders approved the issue of securities under the employee incentive scheme as an exception to ASX Listing Rule 7.1 no more than three years before the date of issue. Accordingly, approval is sought under ASX Listing Rule 7.2 (Exception 9) for the grant of options -under the Plan, so that such grants do not detract from the 15% limit.

### Information required for the purpose of Listing Rule 7.2 (Exception 9)

The following information is provided in accordance with Listing Rule 7.2 (Exception 9):

#### Summary of the Employee Share Option Plan

The following is a summary of the key terms of the Plan:

- Under the Plan, the Board may offer options to employees (including executive directors) of the Company and its related bodies corporate, or such other persons as the Board determines.
- On exercise of an option, the Company will deliver a fully paid ordinary share to the Plan participant. Shares can be delivered by either new issue or on-market purchase.
- The Board will have the discretion to determine the terms and conditions of a grant of options, including:
  - the exercise price (if any);
  - vesting conditions which must be met before the options can be exercised;
  - restrictions on the disposal of or dealing in a share delivered upon the exercise of an option; and
  - whether the shares to be delivered upon the exercise of an option are to be held by a trustee for the benefit of the participant.
- The Plans impose a 5% cap on the number of shares which can be subject to options granted under the Plans, calculated by reference to the Company's total issued share capital and in accordance with the Plans.
- The maximum term of options granted under the Plans will be 5 years, or another period specified by the Board at the time of grant.
- When options are granted, the Board will determine the circumstance in which they will expire, including in relation to the cessation of employment.
- Unless the options granted under the Plan have been exercised and the shares delivered before the relevant record date, a Plan participant cannot participate in new issues of securities to holders of ordinary shares, in relation to those options.
- If the Company makes a pro rata bonus issue of shares or other securities to holders of ordinary shares, and options have not been exercised, then the number of shares subject of the options will be increased by the number of shares that the participant would have received if the options had been exercised before the record date for the bonus issue.





- If the Company makes a pro rata issue of securities (other than a bonus issue) to holders of ordinary shares, the exercise price will be changed in accordance with the ASX Listing Rules.
- In the event of a capital reorganisation, the number of shares subject of each option will be adjusted in accordance with the ASX Listing Rules.
- Options will be forfeited if the applicable vesting conditions are not satisfied, or if the participant commits any act of fraud, defalcation or gross misconduct in relation to the Company or a related body corporate.
- If control of the Company changes, the Board has the discretion to waive any vesting conditions which have not been satisfied.
- The Company may appoint a trustee for the purpose of acquiring and delivering shares to participants and/or holding shares on behalf of participants.
- Participation in the Plan may be extended to participants overseas on essentially the same or a similar basis in Australia, except that the participation may be governed by a different set of rules to accommodate the requirements of local laws and regulatory conditions.
- The Board has certain discretions under the Plan. In particular, the Board may amend the rules of the Plan or waive vesting conditions or disposal restrictions.

Copies of the rules of the Plans are available on request from the Company's registered office.

### **Securities issued under the Plan**

The number of securities issued under the Plan since the date of the last approval is 5,420,000 options.

### **Voting exclusion statement**

The Company will disregard any votes cast on this resolution by a Director who may participate in any employee incentive scheme of the Company and any associate of that Director. However, the Company need not disregard a vote if:

- it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

A member of key management personnel and their closely related parties may not vote as a proxy on this resolution if the appointment does not specify how the proxy is to vote. However, the Chairman can vote undirected proxies provided that the proxy expressly authorises the Chairman to do so.

### **Board Recommendation**

The Board unanimously recommends that shareholders vote in favour of this resolution.

The Chairman intends to vote undirected proxies in favour of this resolution.

## **Item 6 - Cogstate Non-Executive Director Share Option Plan**

### **Background**

The Board has established the Cogstate Non-Executive Director Share Options Plan (the "**Plan**") to reward non-executive directors in a manner which aligns their long term incentives with the creation of shareholder wealth. The Plan was last approved by shareholders at the Company's 2010 annual general meeting.



## **Purpose of Item 6**

Item 6 seeks shareholder approval for the Plan pursuant to ASX Listing Rule 7.2 (Exception 9).

ASX Listing Rule 7.1 requires shareholder approval for an issue of equity securities if, over a 12 month period, the number of equity securities issued is more than 15% of the number of ordinary shares on issue at the start of that 12 month period.

ASX Listing Rule 7.2 (Exception 9) provides that an issue of equity securities under an employee incentive scheme does not detract from the available 15% limit under ASX Listing Rule 7.1 if shareholders approved the issue of securities under the employee incentive scheme as an exception to ASX Listing Rule 7.1 no more than three years before the date of issue. Accordingly, approval is sought under ASX Listing Rule 7.2 (Exception 9) for the grant of options under the Plan, so that such grants do not detract from the 15% limit.

## **Information required for the purpose of Listing Rule 7.2 (Exception 9)**

The following information is provided in accordance with Listing Rule 7.2 (Exception 9):

### **Summary of the Non-Executive Directors Plans**

- Under the NED Option Plan, the Company may grant options to non-executive directors. The NED Option Plan is on substantially the same terms as the Employee Option Plan. Please refer to the notes for Resolution 5 above for a summary of the Employee Option Plan.
- It should be noted that, notwithstanding the approval sought under exception 9 of ASX Listing Rule 7.2, any proposed grants of options under the Non-Executive Director Option Plan to directors will require separate shareholder approval.
- Under the Non-Executive Director Option Plan, the Company may grant options to non-executive directors.

Copies of the rules of the Plans are available on request from the Company's registered office.

### **Securities issued under the Plan**

The number of securities issued under the Plan[s] since the date of the last approval is 1,500,000 options.

### **Voting exclusion statement**

The Company will disregard any votes cast on this resolution by a Director who may participate in any employee incentive scheme of the Company and any associate of that Director. However, the Company need not disregard a vote if:

- it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

A member of key management personnel and their closely related parties may not vote as a proxy on this resolution if the appointment does not specify how the proxy is to vote. However, the Chairman can vote undirected proxies provided that the proxy expressly authorises the Chairman to do so.

### **Board Recommendation**

The Board unanimously recommends that shareholders vote in favour of this resolution.

The Chairman intends to vote undirected proxies in favour of this resolution.





## QUESTIONS AND COMMENTS BY SHAREHOLDERS AT THE MEETING

In accordance with the Corporations Act, a reasonable opportunity will be given to shareholders to ask questions and make comments on the Financial Report, Directors' Report and the Auditor's Report and on the management of the Company at the meeting.

The auditor of the Company (or their representative) is required to attend the meeting. At the meeting, reasonable opportunity will be given to shareholders to ask the Company's auditor, Pitcher Partners (or their representative), questions relevant to:

- (a) the conduct of the audit;
- (b) the preparation and content of the auditor's report;
- (c) the accounting policies adopted by the Company in relation to the preparation of its financial statements; and
- (d) the independence of the auditor in relation to the conduct of the audit.

Shareholders may also submit a written question to Pitcher Partners if the question is relevant to the content of Pitcher Partners' audit report or the conduct of the audit of the Company's financial report for the year ended 30 June 2014.

Relevant written questions for Pitcher Partners must be received no later than 5:00pm (Melbourne time) on Thursday 16<sup>th</sup> October 2014. A list of those relevant questions will be made available to shareholders attending the Annual General Meeting. The auditor may omit questions that are the same in substance to other questions and questions that are not received in a timely manner.

At the meeting, the Chairman of the meeting will give Pitcher Partners (or their representative) a reasonable opportunity to answer written questions submitted in accordance with the Corporations Act.

If written answers are tabled at the Annual General Meeting, they will be made available to shareholders as soon as practicable after the Annual General Meeting.

Please send any written questions for Pitcher Partners:

- to Link Market Services at the address on the enclosed reply paid envelope; or
- by facsimile to +61 3 9664 1301; or
- to the registered office of the Company at level 2, 255 Bourke Street, Melbourne, Vic, 3000, no later than 5:00pm (Melbourne time) on Thursday 16<sup>th</sup> October 2014.

